[Lupus anticoagulants in patients with systemic lupus erythematosus]. 1996

Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
Second Department of Internal Medicine, School of Medicine, Chiba University, Japan.

Lupus anticoagulants (LA) and anticardiolipin antibodies (aCL) are known as thrombosis-related antiphospholipid antibodies. LA is not as well characterized as aCL, and the relation between LA and aCL is not clarified. Since standardized method for the detection of LA has not been established, we measured LA activities in outpatients with SLE by using two different methods (KCT and dRVVT), and analyzed the characteristics of LA in SLE. LA was detected in 29.8% of all samples (14.3% in both methods, 15.5% in one method). IgG-aCL and IgM-aCL was detected in 38% and 20%, respectively, of all LA positive samples. Though a good correlation was observed between LA activities and IgG-aCL levels, a considerable number of LA positive samples were negative for aCL. This indicated the presence of factors with LA activity other than aCL. On the contrary there was also a high percentage of LA negative samples with positive aCL (42.4% in IgG-aCL, 47.4% in IgM-aCL), suggesting the presence of aCL with poor or low LA activity. These findings showed the heterogeneity of antiphospholipid antibodies both in LA and in aCL. The platelet function tests showed increased platelet adhesiveness and normal platelet aggregation in LA positive patients with SLE even in the inactive phase. The serum levels of factors such as protein C, protein S, antithrombin III and thrombomodulin were within normal range. Clinical features such as hemolytic anemia, thrombosis and abortion were more frequently observed in LA positive population than in LA negative population. The clinical features tend to be different between patients with dRVVT-LA and those with KCT-LA, though not significant. Because of the heterogeneity in LA, a combination of more than two different methods including dRVVT was recommended for the detection and the evaluation of LA.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D010973 Platelet Adhesiveness The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces. Adhesiveness, Platelet,Adhesivenesses, Platelet,Platelet Adhesivenesses
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016682 Lupus Coagulation Inhibitor An antiphospholipid antibody found in association with a variety of diseases (e.g., SYSTEMIC LUPUS ERYTHEMATOSUS and ANTIPHOSPHOLIPID SYNDROME) as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications. Lupus Anticoagulant,Lupus Anticoagulant Autoantibodies,Lupus Anticoagulant Autoantibody,Anticoagulant, Lupus,Coagulation Inhibitor, Lupus,Inhibitor, Lupus Coagulation,Anticoagulant Autoantibody, Lupus,Autoantibody, Lupus Anticoagulant
D017153 Antibodies, Anticardiolipin Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN. Anticardiolipin Antibodies,Anticardiolipin Autoantibodies,Anticardiolipin Autoantibody,Cardiolipin Autoantibodies,Cardiolipin Autoantibody,Anticardiolipin Antibody,Antibody, Anticardiolipin,Autoantibody, Anticardiolipin,Autoantibody, Cardiolipin

Related Publications

Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
July 1983, Medicina clinica,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
October 1975, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
December 1990, Annals of the rheumatic diseases,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
January 1992, Contributions to nephrology,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
September 1963, The Journal of laboratory and clinical medicine,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
January 1980, Nephrologie,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
September 1980, La Nouvelle presse medicale,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
January 1970, Resenha clinico-cientifica,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
November 1978, Blood,
Y Matsuura, and Y Nawata, and S Miike, and M Hiraguri, and Y Kita, and K Kurasawa, and K Takabayashi, and H Oh, and I Iwamoto, and Y Saito
April 1990, Ryumachi. [Rheumatism],
Copied contents to your clipboard!